EMP1 tumor cells drive metastatic relapse.
作者信息
Villarreal Oscar E, Kopetz Scott
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Cell Res. 2023 May;33(5):337-338. doi: 10.1038/s41422-022-00769-w.
Abstract
摘要
相似文献
1
EMP1 tumor cells drive metastatic relapse.EMP1肿瘤细胞驱动转移性复发。
Cell Res. 2023 May;33(5):337-338. doi: 10.1038/s41422-022-00769-w.
2
Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1.上皮膜蛋白 1 通过增强细胞迁移来促进肿瘤转移，这是通过 copine-III 和 Rac1 实现的。
Oncogene. 2018 Oct;37(40):5416-5434. doi: 10.1038/s41388-018-0286-0. Epub 2018 Jun 4.
3
Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling.EMP1 的缺失通过激活 PPARγ 信号促进迁移并赋予对铁死亡的抗性，从而促进人膀胱癌细胞的转移。
Free Radic Biol Med. 2022 Aug 20;189:42-57. doi: 10.1016/j.freeradbiomed.2022.06.247. Epub 2022 Jul 16.
4
EMP1-positive cells found guilty of metastatic relapse in colorectal cancer.在结直肠癌中，EMP1 阳性细胞被判有转移复发罪。
Dev Cell. 2022 Dec 19;57(24):2673-2674. doi: 10.1016/j.devcel.2022.11.017.
5
Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma.上皮膜蛋白1对结直肠癌的细胞生长和转移起负向调节作用。
World J Gastroenterol. 2014 Apr 14;20(14):4001-10. doi: 10.3748/wjg.v20.i14.4001.
6
EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion.上皮膜蛋白1调节半胱天冬酶-9和血管内皮生长因子C的表达，并抑制前列腺癌细胞的增殖和侵袭。
Tumour Biol. 2014 Apr;35(4):3455-62. doi: 10.1007/s13277-013-1456-x. Epub 2013 Dec 13.
7
p53, miR-34a and EMP1-Newly Identified Targets of TFF3 Signaling in Y79 Retinoblastoma Cells.p53、miR-34a 和 EMP1-TFF3 信号在 Y79 视网膜母细胞瘤细胞中的新靶标。
Int J Mol Sci. 2019 Aug 24;20(17):4129. doi: 10.3390/ijms20174129.
8
Association of EMP1 with gastric carcinoma invasion, survival and prognosis.EMP1与胃癌侵袭、生存及预后的关联
Int J Oncol. 2014 Sep;45(3):1091-8. doi: 10.3892/ijo.2014.2488. Epub 2014 Jun 10.
9
Metastatic recurrence in colorectal cancer arises from residual EMP1 cells.结直肠癌的转移复发源于残留的 EMP1 细胞。
Nature. 2022 Nov;611(7936):603-613. doi: 10.1038/s41586-022-05402-9. Epub 2022 Nov 9.
10
EMP1 promotes the malignant progression of osteosarcoma through the IRX2/MMP9 axis.EMP1 通过 IRX2/MMP9 轴促进骨肉瘤的恶性进展。
Panminerva Med. 2020 Sep;62(3):150-154. doi: 10.23736/S0031-0808.20.03913-0.
引用本文的文献
1
The role of the aging process and related factor in promoting progression of resectable pancreatic cancer.衰老过程及相关因素在可切除胰腺癌进展中的作用。
Genes Dis. 2024 Dec 15;12(5):101490. doi: 10.1016/j.gendis.2024.101490. eCollection 2025 Sep.
2
Epithelial membrane protein 1 in human cancer: a potential diagnostic biomarker and therapeutic target.人癌症中的上皮膜蛋白1：一种潜在的诊断生物标志物和治疗靶点。
Biomark Med. 2024;18(21-22):995-1005. doi: 10.1080/17520363.2024.2416887. Epub 2024 Oct 29.
本文引用的文献
1
Metastatic recurrence in colorectal cancer arises from residual EMP1 cells.结直肠癌的转移复发源于残留的 EMP1 细胞。
Nature. 2022 Nov;611(7936):603-613. doi: 10.1038/s41586-022-05402-9. Epub 2022 Nov 9.
2
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.局部晚期直肠癌患者免疫治疗的发展态势
Cancers (Basel). 2022 Sep 14;14(18):4453. doi: 10.3390/cancers14184453.
3
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
4
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.新辅助免疫治疗导致 MMR 功能正常和 MMR 缺陷的早期结肠癌发生病理应答。
Nat Med. 2020 Apr;26(4):566-576. doi: 10.1038/s41591-020-0805-8. Epub 2020 Apr 6.
5
Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer.Lgr5 阴性癌细胞的可塑性驱动结直肠癌转移。
Cell Stem Cell. 2020 Apr 2;26(4):569-578.e7. doi: 10.1016/j.stem.2020.02.008. Epub 2020 Mar 12.
6
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.实体瘤中循环肿瘤DNA定义的微小残留病：加速辅助治疗发展的机遇
J Clin Oncol. 2018 Oct 30;36(35):JCO2018789032. doi: 10.1200/JCO.2018.78.9032.
7
Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?靶向结直肠癌中的 LGR5：治疗的黄金还是太灵活？
Br J Cancer. 2018 May;118(11):1410-1418. doi: 10.1038/s41416-018-0118-6. Epub 2018 May 30.
8
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.TGFβ 驱动基因重建的结肠癌转移中的免疫逃逸。
Nature. 2018 Feb 22;554(7693):538-543. doi: 10.1038/nature25492. Epub 2018 Feb 14.
9
Targeting minimal residual disease: a path to cure?靶向微小残留病灶：治愈之路？
Nat Rev Cancer. 2018 Apr;18(4):255-263. doi: 10.1038/nrc.2017.125. Epub 2018 Jan 29.
10
A distinct role for Lgr5 stem cells in primary and metastatic colon cancer.Lgr5 干细胞在原发性和转移性结肠癌中的独特作用。
Nature. 2017 Mar 29;543(7647):676-680. doi: 10.1038/nature21713.
Zotero 插件